We are delighted to be featured in the latest issue of VentureCapital Magazine, which spotlights the Dresden region as a high-performance hub for key players and innovators in radiopharmaceutical innovation.
ROTOP Pharmaka is recognized as a leading manufacturer of radiopharmaceuticals, including an iodine-123 compound used in Parkinson’s diagnostics. The article also emphasizes the strong network we are part of – combining research collaborations, advanced manufacturing, and the development of innovative theranostic solutions – and highlights how this ecosystem is driving meaningful progress in patient care.
Original Source: https://bc-production.pressmatrix.com/de/profiles/98d522283e29/editions
Have a look at the VentureCapital Magazine: https://bc-production.pressmatrix.com/de/profiles/98d522283e29/editions/d0f1f2c05ace72a5f55d
Ähnliche Beiträge
ROTOP Receives Building Permit for New Radiopharmaceutical Manufacturing Facility in Dresden
April 27, 2026 - ROTOP Pharmaka GmbH today announced that it has received the building permit for a new radiopharmaceutical manufacturing facility in Dresden. The approval represents a major step in the company’s growth strategy and further strengthens its position as a leading radiopharmaceutical partner in Europe.
New CFO at ROTOP – Dr. Michael Peterseim
March 13, 2026 - We’re pleased to Welcome Dr. Michael Peterseim as our new Chief Financial Officer (CFO) at ROTOP. Dr. Peterseim brings many years of experience in financial leadership and has successfully guided companies through transformation processes, strengthened performance, and executed strategic transactions, particularly in growth situations.
ROTOP Pharmaka Welcomes State Minister Dirk Panter: Radiopharmacy as a Key Technology in Modern Cancer Care
January 9, 2026 - ROTOP Pharmaka welcomed Saxony’s State Minister Dirk Panter during the region’s Radiopharmacy Theme Day. The exchange highlighted the importance of modern radiopharmacy for cancer care as well as ROTOP’s contribution through diagnostics, ready to use patient doses, and CDMO services, with a particular focus on theranostic concepts.
